Why the study?
Despite its negative clinical consequences in heart failure, iron deficiency remains under-recognised, prompting the need for practical guidance on screening, diagnosing, and treating it.
Answers are grounded in this paper and cite their sources.
This review provides practical guidance on screening, diagnosing, and treating iron deficiency in patients with HFrEF using intravenous iron, in alignment with the 2021 ESC guidelines.
Iron deficiency (ID) is a comorbid condition frequently seen in patients with heart failure (HF). Iron has an important role in the transport of oxygen, and is also essential for skeletal and cardiac muscle, which depend on iron for oxygen storage and cellular energy production. Thus, ID per se, even without anaemia, can be harmful. In patients with HF, ID is associated with a poorer quality of life (QoL) and exercise capacity, and a higher risk of hospitalisations and mortality, even in the absence of anaemia. Despite its negative clinical consequences, ID remains under-recognised. However, it is easily diagnosed and managed, and the recently revised 2021 European Society of Cardiology (ESC) guidelines on HF provide specific recommendations for its diagnosis and treatment. Prospective randomised controlled trials in patients with symptomatic HF with reduced ejection fraction (HFrEF) show that correction of ID using intravenous iron (principally ferric carboxymaltose [FCM]) provides improvements in symptoms of HF, exercise capacity and QoL, and a recent trial demonstrated that FCM therapy following hospitalisation due to acute decompensated HF reduced the risk of subsequent HF hospitalisations. This review provides a summary of the epidemiology and pathophysiology of ID in HFrEF, and practical guidance on screening, diagnosing, and treating ID.
No takes yet. Share an insight, caveat, or question.
Sindone et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: